atenolol has been researched along with Obesity in 29 studies
Atenolol: A cardioselective beta-1 adrenergic blocker possessing properties and potency similar to PROPRANOLOL, but without a negative inotropic effect.
atenolol : An ethanolamine compound having a (4-carbamoylmethylphenoxy)methyl group at the 1-position and an N-isopropyl substituent.
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Combination therapy of nitrendipine and atenolol may significantly increase BW and fasting BG in overweight or obese patients with hypertension." | 9.14 | Effect of metformin on weight gain during antihypertensive treatment with a beta-blocker in Chinese patients. ( Qin, YW; Qiu, JL; Zhang, JL; Zhao, XX; Zheng, X; Zou, DJ, 2009) |
| " We investigated whether body build was independently associated with higher cardiovascular risk and whether treatment with losartan relative to atenolol influenced the impact of body build on the primary composite end point of cardiovascular death, stroke, and myocardial infarction and on cardiovascular death in patients with hypertension and left ventricular hypertrophy in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study." | 9.11 | Body build and risk of cardiovascular events in hypertension and left ventricular hypertrophy: the LIFE (Losartan Intervention For Endpoint reduction in hypertension) study. ( Beevers, G; Dahlöf, B; de Faire, U; de Simone, G; Devereux, RB; Fyhrquist, F; Hille, DA; Ibsen, H; Julius, S; Kjeldsen, SE; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Palmieri, V; Wachtell, K, 2005) |
| "The present study investigated the effect of the new ACE-inhibitor moexipril versus the beta 1-adrenergic blocker atenolol on metabolic parameters, adverse events (AEs) and sitting systolic (SSBP) and sitting diastolic blood pressure (SDBP) in obese postmenopausal women with hypertension (stage I and II)." | 9.08 | Comparison between moexipril and atenolol in obese postmenopausal women with hypertension. ( Koch, B; Stimpel, M; Weber, MA, 1998) |
| "To investigate the involvement of adrenergic mechanisms in the development of obesity, hyperglycaemia and hyperinsulinaemia in Aston ob/ob mice, the sympathomimetic agent ephedrine (12 mg/kg/day) and the predominantly beta 1-adrenergic antagonist atenolol (12 mg/kg/day) were administered alone and in combination to weanling ob/ob mice for 40 days." | 7.67 | Effects of ephedrine and atenolol on the development of obesity and diabetes in ob/ob mice. ( Bailey, CJ; Flatt, PR; Thornburn, CC, 1986) |
| "Combination therapy of nitrendipine and atenolol may significantly increase BW and fasting BG in overweight or obese patients with hypertension." | 5.14 | Effect of metformin on weight gain during antihypertensive treatment with a beta-blocker in Chinese patients. ( Qin, YW; Qiu, JL; Zhang, JL; Zhao, XX; Zheng, X; Zou, DJ, 2009) |
| " We investigated whether body build was independently associated with higher cardiovascular risk and whether treatment with losartan relative to atenolol influenced the impact of body build on the primary composite end point of cardiovascular death, stroke, and myocardial infarction and on cardiovascular death in patients with hypertension and left ventricular hypertrophy in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study." | 5.11 | Body build and risk of cardiovascular events in hypertension and left ventricular hypertrophy: the LIFE (Losartan Intervention For Endpoint reduction in hypertension) study. ( Beevers, G; Dahlöf, B; de Faire, U; de Simone, G; Devereux, RB; Fyhrquist, F; Hille, DA; Ibsen, H; Julius, S; Kjeldsen, SE; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Palmieri, V; Wachtell, K, 2005) |
| "The present study investigated the effect of the new ACE-inhibitor moexipril versus the beta 1-adrenergic blocker atenolol on metabolic parameters, adverse events (AEs) and sitting systolic (SSBP) and sitting diastolic blood pressure (SDBP) in obese postmenopausal women with hypertension (stage I and II)." | 5.08 | Comparison between moexipril and atenolol in obese postmenopausal women with hypertension. ( Koch, B; Stimpel, M; Weber, MA, 1998) |
| " They were randomized to a usual diet (n = 296) or to a weight loss diet (n = 291) and within each diet group to placebo, chlorthalidone, 25 mg/d, or atenolol, 50 mg/d." | 5.07 | Reduction in long-term antihypertensive medication requirements. Effects of weight reduction by dietary intervention in overweight persons with mild hypertension. ( Blaufox, MD; Cutler, JA; Davis, BR; Kirchner, K; Langford, HG; Oberman, A; Wassertheil-Smoller, S; Zimbaldi, N, 1993) |
| " Aim of this work was to evaluate the influence of obesity on the kinetics and the antihypertensive effect of two Beta-blockers with different solubility such as: the water-soluble, atenolol and the liposoluble, metoprolol." | 5.06 | Obesity and beta-blockers: influence of body fat on their kinetics and cardiovascular effects. ( Fasano, ML; Ferrara, LA; Galletti, F; Groppi, A; Mancini, M; Montagna, M, 1989) |
| "001), a sub-analysis on those with hypertension diagnosis confirmed that only the hypertensive population taking atenolol had a significantly larger population of obese individuals (BMI ≥25) compared with those who took metoprolol (58." | 3.96 | Association between beta-blocker use and obesity in Hong Kong Chinese elders: a post-hoc analysis. ( Bajorek, B; Fong, W; Freedman, B; Lee, VWY; Leung, KL, 2020) |
| "To investigate the involvement of adrenergic mechanisms in the development of obesity, hyperglycaemia and hyperinsulinaemia in Aston ob/ob mice, the sympathomimetic agent ephedrine (12 mg/kg/day) and the predominantly beta 1-adrenergic antagonist atenolol (12 mg/kg/day) were administered alone and in combination to weanling ob/ob mice for 40 days." | 3.67 | Effects of ephedrine and atenolol on the development of obesity and diabetes in ob/ob mice. ( Bailey, CJ; Flatt, PR; Thornburn, CC, 1986) |
| "The lipophilic beta-adrenoreceptor antagonist propranolol and hydrophilic atenolol have been studied to define their pharmacokinetic and pharmacodynamic characteristics in obese patients." | 2.71 | Comparative pharmacokinetics and pharmacodynamics of propranolol and atenolol in normolipaemic and hyperlipidaemic obese subjects. ( Droździk, M; Gawrońska-Szklarz, B; Jaroszynska, M; Pawlik, A; Sterna, R; Wójcicki, J, 2003) |
| "Blood pressure and proteinuria are important determinants of progressive renal failure in patients with renal diseases." | 2.41 | [Intensive treatment of blood pressure in patients with kidney disease and proteinuria]. ( Huysmans, FT; Wetzels, JF, 2000) |
| " Levels of erythrocyte cellular superoxide dismutase increased with nebivolol, indirectly suggesting increased bioavailability of nitric oxide (P<." | 1.35 | Nebivolol in high-risk, obese African Americans with stage 1 hypertension: effects on blood pressure, vascular compliance, and endothelial function. ( Ferdinand, KC; Khan, BV; Merchant, N; Pandian, A; Rahman, ST; Searles, CD; Umpierrez, GE, 2009) |
| "Only clonidine treatment totally prevented the development of insulin resistance, and high-dose aspirin, known to prevent insulin resistance by inhibition of the activity of IkappaB kinase-beta, decreased the degree of insulin resistance by almost 70%." | 1.32 | Hypertension and insulin resistance are not directly related in obese dogs. ( Gokee, A; Rocchini, AP; Yang, JQ, 2004) |
| "Pretreatment with atenolol (50 or 100 mg orally in subjects with body weight less than or greater than 40 kg, respectively, administered 120 min before the GHRH injection) significantly increased the GH response to GHRH in the obese subjects, such that their mean peak GH levels and mean integrated area under the curve after atenolol plus GHRH were similar to those of the control children after GHRH." | 1.28 | The effect of atenolol on the growth hormone response to growth hormone-releasing hormone in obese children. ( Carta, D; Civolani, P; Congiu, G; Loche, S; Muntoni, AC; Pintor, C; Pintus, S, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (6.90) | 18.7374 |
| 1990's | 12 (41.38) | 18.2507 |
| 2000's | 13 (44.83) | 29.6817 |
| 2010's | 1 (3.45) | 24.3611 |
| 2020's | 1 (3.45) | 2.80 |
| Authors | Studies |
|---|---|
| Xie, F | 1 |
| Yang, F | 1 |
| Liang, Y | 1 |
| Li, L | 1 |
| Xia, Y | 1 |
| Jiang, F | 1 |
| Liu, W | 1 |
| Qi, Y | 1 |
| Chowdhury, SR | 1 |
| Xie, D | 1 |
| Fu, L | 1 |
| Leung, KL | 1 |
| Fong, W | 1 |
| Freedman, B | 1 |
| Bajorek, B | 1 |
| Lee, VWY | 1 |
| Zhang, JL | 1 |
| Zheng, X | 1 |
| Zou, DJ | 1 |
| Qiu, JL | 1 |
| Zhao, XX | 1 |
| Qin, YW | 1 |
| Merchant, N | 1 |
| Searles, CD | 1 |
| Pandian, A | 1 |
| Rahman, ST | 1 |
| Ferdinand, KC | 1 |
| Umpierrez, GE | 1 |
| Khan, BV | 1 |
| Wójcicki, J | 1 |
| Jaroszynska, M | 1 |
| Droździk, M | 1 |
| Pawlik, A | 1 |
| Gawrońska-Szklarz, B | 1 |
| Sterna, R | 1 |
| Talbert, RL | 1 |
| Pieper, JA | 1 |
| Ito, MK | 1 |
| Rocchini, AP | 1 |
| Yang, JQ | 1 |
| Gokee, A | 1 |
| de Simone, G | 1 |
| Wachtell, K | 1 |
| Palmieri, V | 1 |
| Hille, DA | 1 |
| Beevers, G | 1 |
| Dahlöf, B | 1 |
| de Faire, U | 1 |
| Fyhrquist, F | 1 |
| Ibsen, H | 1 |
| Julius, S | 1 |
| Kjeldsen, SE | 1 |
| Lederballe-Pedersen, O | 1 |
| Lindholm, LH | 1 |
| Nieminen, MS | 1 |
| Omvik, P | 1 |
| Oparil, S | 1 |
| Devereux, RB | 1 |
| Jordan, J | 2 |
| Engeli, S | 2 |
| Boschmann, M | 2 |
| Weidinger, G | 3 |
| Luft, FC | 2 |
| Sharma, AM | 2 |
| Kreuzberg, U | 2 |
| Adams, F | 1 |
| Franke, G | 1 |
| Klaua, S | 1 |
| Scholze, J | 1 |
| Kaaja, R | 1 |
| Kujala, S | 1 |
| Manhem, K | 1 |
| Katzman, P | 1 |
| Kibarskis, A | 1 |
| Antikainen, R | 1 |
| Ylihärsilä, H | 1 |
| Erkkola, R | 1 |
| Tuomilehto, J | 1 |
| Uretsky, S | 1 |
| Messerli, FH | 1 |
| Bangalore, S | 1 |
| Champion, A | 1 |
| Cooper-Dehoff, RM | 1 |
| Zhou, Q | 1 |
| Pepine, CJ | 1 |
| Morel, Y | 1 |
| Gadient, A | 1 |
| Keller, U | 1 |
| Vadas, L | 1 |
| Golay, A | 1 |
| Davis, BR | 3 |
| Oberman, A | 3 |
| Blaufox, MD | 3 |
| Wassertheil-Smoller, S | 3 |
| Zimbaldi, N | 3 |
| Kirchner, K | 2 |
| Wylie-Rosett, J | 2 |
| Langford, HG | 3 |
| Blaak, EE | 3 |
| van Baak, MA | 3 |
| Kemerink, GJ | 3 |
| Pakbiers, MT | 3 |
| Heidendal, GA | 3 |
| Saris, WH | 3 |
| Cutler, JA | 1 |
| Jennings, S | 1 |
| Hataway, H | 1 |
| Stern, J | 1 |
| Bönner, G | 1 |
| Schmieder, R | 1 |
| Chrosch, R | 1 |
| Stimpel, M | 1 |
| Koch, B | 1 |
| Weber, MA | 1 |
| Kuperstein, R | 1 |
| Sasson, Z | 1 |
| Huysmans, FT | 1 |
| Wetzels, JF | 1 |
| Wofford, MR | 1 |
| Anderson, DC | 1 |
| Brown, CA | 1 |
| Jones, DW | 1 |
| Miller, ME | 1 |
| Hall, JE | 1 |
| Loche, S | 1 |
| Pintus, S | 1 |
| Carta, D | 1 |
| Muntoni, AC | 1 |
| Congiu, G | 1 |
| Civolani, P | 1 |
| Pintor, C | 1 |
| Johannesson, M | 1 |
| Fagerberg, B | 1 |
| Bürgi, U | 1 |
| Bürgi-Saville, ME | 1 |
| Burgherr, J | 1 |
| Clément, M | 1 |
| Lauber, K | 1 |
| Galletti, F | 1 |
| Fasano, ML | 1 |
| Ferrara, LA | 1 |
| Groppi, A | 1 |
| Montagna, M | 1 |
| Mancini, M | 1 |
| Bailey, CJ | 1 |
| Thornburn, CC | 1 |
| Flatt, PR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Triple-Blind, Parallel Study to Investigate the Effect of Losartan Versus Atenolol on the Reduction of Morbidity and Mortality in Hypertensive Patients With Left Ventricular Hypertrophy[NCT00338260] | Phase 3 | 496 participants (Actual) | Interventional | 1995-06-30 | Completed | ||
| Comparative Study of Effect of Valsartan 160mg Treatment Versus Continuous Positive Airway Pressure on Arterial Blood Pressure in Patients Who Have an Obstructive Sleep Apnea Syndrome and a Weak or Moderate Hypertension.[NCT00409487] | Phase 4 | 60 participants (Anticipated) | Interventional | 2006-12-31 | Completed | ||
| INternational VErapamil SR Trandolapril STudy[NCT00133692] | Phase 4 | 22,000 participants | Interventional | 1997-09-30 | Completed | ||
| [NCT00000513] | Phase 3 | 0 participants | Interventional | 1984-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for atenolol and Obesity
| Article | Year |
|---|---|
[Intensive treatment of blood pressure in patients with kidney disease and proteinuria].
Topics: Antihypertensive Agents; Atenolol; Chlorthalidone; Dose-Response Relationship, Drug; Enalapril; Glom | 2000 |
17 trials available for atenolol and Obesity
| Article | Year |
|---|---|
Effect of metformin on weight gain during antihypertensive treatment with a beta-blocker in Chinese patients.
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Blood Glucose; Body Mass Index | 2009 |
Comparative pharmacokinetics and pharmacodynamics of propranolol and atenolol in normolipaemic and hyperlipidaemic obese subjects.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Area Under Curve; Atenolol; Blood Pressure | 2003 |
Body build and risk of cardiovascular events in hypertension and left ventricular hypertrophy: the LIFE (Losartan Intervention For Endpoint reduction in hypertension) study.
Topics: Aged; Atenolol; Body Mass Index; Body Weight; Cardiovascular Diseases; Female; Humans; Hypertension; | 2005 |
Hemodynamic and metabolic responses to valsartan and atenolol in obese hypertensive patients.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive | 2005 |
The effect of oral glucose loads on tissue metabolism during angiotensin II receptor and beta-receptor blockade in obese hypertensive subjects.
Topics: Adipose Tissue; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Atenolol; Blo | 2006 |
Effects of sympatholytic therapy on insulin sensitivity indices in hypertensive postmenopausal women.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Double-Blind Method; Female; Finland | 2007 |
Obesity paradox in patients with hypertension and coronary artery disease.
Topics: Age Distribution; Aged; Antihypertensive Agents; Atenolol; Body Mass Index; Causality; Cohort Studie | 2007 |
Insulin sensitivity in obese hypertensive dyslipidemic patients treated with enalapril or atenolol.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aten | 1995 |
Lack of effectiveness of a low-sodium/high-potassium diet in reducing antihypertensive medication requirements in overweight persons with mild hypertension. TAIM Research Group. Trial of Antihypertensive Interventions and Management.
Topics: Adult; Antihypertensive Agents; Atenolol; Chlorthalidone; Combined Modality Therapy; Diet, Sodium-Re | 1994 |
Reduction in long-term antihypertensive medication requirements. Effects of weight reduction by dietary intervention in overweight persons with mild hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Atenolol; Chlorthalidone; Female; Humans; Hypertension; Male; | 1993 |
Trial of antihypertensive intervention and management: greater efficacy with weight reduction than with a sodium-potassium intervention.
Topics: Adult; Analysis of Variance; Atenolol; Blood Pressure; Body Weight; Chlorthalidone; Combined Modalit | 1993 |
Effect of bunazosin and atenolol on glucose metabolism in obese, nondiabetic patients with primary hypertension.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Blood | 1997 |
Comparison between moexipril and atenolol in obese postmenopausal women with hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Atenolol; Female | 1998 |
Effects of antihypertensive therapy on glucose and insulin metabolism and on left ventricular mass: A randomized, double-blind, controlled study of 21 obese hypertensives.
Topics: Antihypertensive Agents; Atenolol; Double-Blind Method; Female; Glucose; Heart Ventricles; Humans; H | 2000 |
Antihypertensive effect of alpha- and beta-adrenergic blockade in obese and lean hypertensive subjects.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Atenolol; Blood Pressure Monitorin | 2001 |
A health-economic comparison of diet and drug treatment in obese men with mild hypertension.
Topics: Adult; Aged; Atenolol; Cholesterol; Cholesterol, HDL; Computer Simulation; Cost-Benefit Analysis; Hu | 1992 |
Obesity and beta-blockers: influence of body fat on their kinetics and cardiovascular effects.
Topics: Adipose Tissue; Atenolol; Blood Pressure; Female; Heart Rate; Humans; Hypertension; Kinetics; Male; | 1989 |
11 other studies available for atenolol and Obesity
| Article | Year |
|---|---|
Investigation of stereoisomeric bisarylethenesulfonic acid esters for discovering potent and selective PTP1B inhibitors.
Topics: Animals; Antigens, CD; Cell Membrane Permeability; Diabetes Mellitus, Type 2; Esters; Glucose; Human | 2019 |
Association between beta-blocker use and obesity in Hong Kong Chinese elders: a post-hoc analysis.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Asian People; Atenolol; Blood Pressure; Body M | 2020 |
Nebivolol in high-risk, obese African Americans with stage 1 hypertension: effects on blood pressure, vascular compliance, and endothelial function.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Antihypertensive Agents; Atenolol; Benzopyrans | 2009 |
Niacin and the National Cholesterol Education Program Adult Treatment Panel III Guidelines: case studies.
Topics: Aspirin; Atenolol; Blood Chemical Analysis; Coronary Disease; Female; Humans; Hyperlipidemias; Hyper | 2003 |
Hypertension and insulin resistance are not directly related in obese dogs.
Topics: Adrenergic beta-Antagonists; Animals; Aspirin; Atenolol; Blood Glucose; Clonidine; Diet, Sodium-Rest | 2004 |
Beta-adrenergic stimulation and abdominal subcutaneous fat blood flow in lean, obese, and reduced-obese subjects.
Topics: Abdominal Muscles; Adipose Tissue; Adult; Atenolol; Body Composition; Diet; Humans; Injections, Intr | 1995 |
Beta-adrenergic stimulation of energy expenditure and forearm skeletal muscle metabolism in lean and obese men.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Adult; Atenolol; Body Temperature Regulation; | 1994 |
beta-Adrenergic stimulation of skeletal muscle metabolism in relation to weight reduction in obese men.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Adult; Atenolol; Body Composition; Fatty Acid | 1994 |
The effect of atenolol on the growth hormone response to growth hormone-releasing hormone in obese children.
Topics: Atenolol; Child; Child, Preschool; Female; Growth Hormone; Growth Hormone-Releasing Hormone; Humans; | 1992 |
T3 plus high doses of beta-blockers: effects on energy intake, body composition, bat and heart in rats.
Topics: Adipose Tissue; Adipose Tissue, Brown; Adrenergic beta-Antagonists; Animals; Atenolol; Body Composit | 1990 |
Effects of ephedrine and atenolol on the development of obesity and diabetes in ob/ob mice.
Topics: Aging; Animals; Atenolol; Blood Glucose; Body Weight; Diabetes Mellitus; Diabetes Mellitus, Experime | 1986 |